TW200812955A - Anti cancer use of caffeic acid and derivatives - Google Patents

Anti cancer use of caffeic acid and derivatives Download PDF

Info

Publication number
TW200812955A
TW200812955A TW096131151A TW96131151A TW200812955A TW 200812955 A TW200812955 A TW 200812955A TW 096131151 A TW096131151 A TW 096131151A TW 96131151 A TW96131151 A TW 96131151A TW 200812955 A TW200812955 A TW 200812955A
Authority
TW
Taiwan
Prior art keywords
abl
bcr
dihydroxyphenyl
propenone
compound
Prior art date
Application number
TW096131151A
Other languages
English (en)
Chinese (zh)
Inventor
Kalpana Sanjay Joshi
Meenakshi Sivakumar
Valmik Sopan Aware
Vilas Sampatrao Wagh
Amit Deshpande
Gangaram Sarde Ankush
Sharma Somesh
Original Assignee
Nicholas Piramal India Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nicholas Piramal India Ltd filed Critical Nicholas Piramal India Ltd
Publication of TW200812955A publication Critical patent/TW200812955A/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4453—Non condensed piperidines, e.g. piperocaine only substituted in position 1, e.g. propipocaine, diperodon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
TW096131151A 2006-09-01 2007-08-22 Anti cancer use of caffeic acid and derivatives TW200812955A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US84206006P 2006-09-01 2006-09-01

Publications (1)

Publication Number Publication Date
TW200812955A true TW200812955A (en) 2008-03-16

Family

ID=39015871

Family Applications (1)

Application Number Title Priority Date Filing Date
TW096131151A TW200812955A (en) 2006-09-01 2007-08-22 Anti cancer use of caffeic acid and derivatives

Country Status (12)

Country Link
US (1) US20100010002A1 (enExample)
EP (1) EP2061452B1 (enExample)
JP (1) JP2010502586A (enExample)
AT (1) ATE530176T1 (enExample)
AU (1) AU2007290960B2 (enExample)
CA (1) CA2662126A1 (enExample)
DK (1) DK2061452T3 (enExample)
ES (1) ES2376277T3 (enExample)
IL (1) IL197262A0 (enExample)
PT (1) PT2061452E (enExample)
TW (1) TW200812955A (enExample)
WO (1) WO2008026125A2 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010052732A1 (en) * 2008-11-07 2010-05-14 Council Of Scientific & Industrial Research Cinnamido-pvrrolor[2,1-c][1,4]benzodiazepines as potential anticancer agents and process for the preparation thereof
CN101456890B (zh) * 2008-12-17 2011-02-02 中南大学 白血病bcr/abl融合基因mRNA的特异性抑制剂
WO2010127440A1 (en) 2009-05-04 2010-11-11 Prometic Biosciences Inc. Substituted aromatic compounds and pharmaceutical uses thereof
KR20130010895A (ko) 2010-02-25 2013-01-29 피라말 엔터프라이지즈 리미티드 옥사디아졸 화합물, 그의 제조방법 및 용도
DK3443957T3 (da) 2010-10-27 2020-12-21 Liminal Biosciences Ltd Forbindelser og sammensætninger til behandling af cancer
US20140127316A1 (en) * 2011-05-20 2014-05-08 New York University Propolis and caffeic acid phenethyl ester and uses thereof
US20160194718A1 (en) * 2013-05-21 2016-07-07 Dana-Farber Cancer Institute, Inc. Compositions and Methods for Identification, Assessment, Prevention, and Treatment of Cancer Using Histone H3K27ME3 Biomarkers and Modulators
WO2017161093A1 (en) * 2016-03-17 2017-09-21 Musc Foundation For Research Development Caffeic acid derivatives and uses thereof
US20220370385A1 (en) * 2019-09-17 2022-11-24 Enzene Biosciences Ltd. Compositions for use in inhibiting src kinase and treating and preventing associated disorders
US11878971B2 (en) 2020-12-29 2024-01-23 Huscion Co., Ltd. Piperlongumine-based compound and immuno regulator comprising the same
EP4277896A4 (en) * 2021-01-14 2025-03-05 B.G. Negev Technologies and Applications Ltd., at Ben-Gurion University COMPOUNDS FOR STIMULATING AGAINST GASTRIC BIOFILM AND REDUCE INFLAMMATION, COMPOSITIONS AND METHODS OF USE THEREOF

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5216024A (en) * 1987-07-28 1993-06-01 Baylor College Of Medicine Cell growth inhibitors and methods of treating cancer and cell proliferative diseases
US5008441A (en) * 1987-08-04 1991-04-16 The Trustees Of Columbia University In The City Of New York Caffeic acid esters and methods of producing and using same
EP1511475B1 (en) * 2002-05-31 2005-10-05 Council of Scientific and Industrial Research A herbal molecule as potential anti-leukemic drug
US20040006138A1 (en) * 2002-07-08 2004-01-08 Council Of Scientific Pharmaceutical composition useful for treating chronic myeloid leukemia
US20050282892A1 (en) * 2002-07-08 2005-12-22 Santu Bandyopadhyay Pharmaceutical composition useful for treating chronic myeloid leukemia
US20070161704A1 (en) * 2002-07-08 2007-07-12 Council Of Scientific And Industrial Research Pharmaceutical composition useful for treating chronic myeloid leukemia
AU2003201062A1 (en) * 2002-07-08 2004-01-23 Council Of Scientific And Industrial Research A pharmaceutical composition useful for treating chronic myeloid leukemia
WO2005099721A2 (en) * 2004-04-15 2005-10-27 The Regents Of The University Of California Compositions comprising plant-derived polyphenolic compounds and inhibitors of reactive oxygen species and methods of using thereof
US20060045887A1 (en) 2004-08-25 2006-03-02 Gavish-Galilee Bio Applications Ltd. Mushroom extracts having anticancer activity

Also Published As

Publication number Publication date
CA2662126A1 (en) 2008-03-06
US20100010002A1 (en) 2010-01-14
PT2061452E (pt) 2012-01-13
JP2010502586A (ja) 2010-01-28
AU2007290960B2 (en) 2013-04-18
DK2061452T3 (da) 2012-02-13
WO2008026125A3 (en) 2008-10-02
EP2061452B1 (en) 2011-10-26
IL197262A0 (en) 2009-12-24
EP2061452A2 (en) 2009-05-27
AU2007290960A1 (en) 2008-03-06
WO2008026125A2 (en) 2008-03-06
ES2376277T3 (es) 2012-03-12
ATE530176T1 (de) 2011-11-15

Similar Documents

Publication Publication Date Title
TW200812955A (en) Anti cancer use of caffeic acid and derivatives
US11951109B2 (en) EZH2 inhibitors for treating lymphoma
US11147819B2 (en) EZH2 inhibitors for treating cancer
US9365547B2 (en) Substituted pyridinone-pyridinyl compounds
TWI357901B (en) Substituted morpholine and thiomorpholine derivati
US11154544B2 (en) Amide derivatives as Nav1.7 and Nav1.8 blockers
TW201629065A (zh) 三唑并嘧啶化合物及其用途
EA038337B1 (ru) Ингибиторы ezh2 для лечения лимфомы
US20210379043A1 (en) Combination treatment of liver disorders
EP4309738A2 (en) Method of treating medulloblastoma with an ezh2 inhibitor
JP2010502586A5 (enExample)
US20230130766A1 (en) Mono and combination therapies with ulk1/2 inhibitors
KR20220066290A (ko) Perk 억제 피롤로피리미딘 화합물
US11465978B2 (en) Anthranilic amides and the use thereof
JP2013515766A (ja) イマチニブジクロロ酢酸塩及びそれを含む抗癌剤組成物
US20070203153A1 (en) Compositions and methods for treating thrombocytopenia
US11465994B2 (en) MGluR7 agonist compounds for treating mGluR7-regulated diseases, disorders, or conditions
WO2017082377A1 (ja) ピラゾロピリジン誘導体およびその使用
CN106986859B (zh) 吲哚衍生物及其用途
TW200831463A (en) Nitrate esters of aminoalcohols
CN108752360B (zh) 一种治疗小儿腹泻的化合物及其制备方法
JP2023507799A (ja) 組み合わせ